Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 584 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

FDA approves Aegerion’s Juxtapid capsule

Juxtapid, which is a supplement to fat reduction treatments also includes availability of LDL apheresis, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B)